Compounding Chemotherapy Market Size was valued at USD 0.50 Billion in 2023. The Compounding Chemotherapy industry is projected to grow from USD 0.53 Billion in 2024 to USD 0.84 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.01% during the forecast period (2024 - 2032). An increase in the prevalence of illnesses, including cancer, bone marrow conditions, and immune system issues, increasing costs for prescription drugs and changing payment policies are just a few of the market drivers driving the market.
Pharmaceutical R&D is anticipated to provide market participants with a profitable development potential for treating various ailments in innovative media, forms, and dosages. Manufacturers will profit from the rising adoption of veterinary and animal pharmaceutical compounding, notably in Europe and North America. If compounding pharmacies wish to boost their earnings, they must implement hybrid retail techniques in addition to a compounding department. To lessen mistakes caused by sterile Compounding, market players must focus more on non-sterile Compounding pharmacies. Major Compounding Chemotherapy industry players largely focus on worldwide growth and the launch of cutting-edge goods that address the customers wants to expand their market share. Large medical and pharmaceutical firms collaborate with smaller compounding solution providers and research institutes in the Asia Pacific and Europe to enhance their market positioning and create sustainable positioning. North America, Europe, and Asia-Pacific are currently the target markets for large compounding pharmacies.
Additionally, the FDA's increasing acceptance of new pharmaceutical applications and corporate alliances encourage the usage of high-quality medicines and goods. Compounding pharmacies' sales may soon rise since regulatory processes in developing countries are anticipated to be simplified and enhanced. Thus, this factor is driving the Compounding Chemotherapy market CAGR.
Due to various factors, including poor skincare habits, bad eating habits, and a family medical history of the illness, the incidence of skin problems is increasing in North America. Acute disorders like dermatitis and melanoma are spreading with alarming frequency. According to the American Academy of Dermatology, 7.5 million Americans suffer from the chronic skin condition psoriasis (AAD). These medical issues have boosted the need for online compounding pharmacies that create the proper medication to prevent allergies or other unfavorable medical responses upon absorption of the meds. The Compounding Chemotherapy market in this area will grow due to rising elderly populations and life expectancy rates. In the European region, there will be roughly 40 million individuals who are 85 years of age or older by 2050, according to the World Health Organization (WHO).
The extended longevity of the older population has raised the demand for customized treatment. Because more people are surviving old age and there is a greater desire to look young, there is a greater demand for anti-aging therapies and goods like bioidentical hormone replacement therapy and human growth hormone. Similarly, increasing testosterone treatment and premium dermatological products among the elderly will spur growth in these industries because many are mostly developed in Compounding. Thus, it is anticipated that this aspect will accelerate the Compounding Chemotherapy market revenue globally.
Based on Dose, the Compounding Chemotherapy market segmentation includes Chemotherapeutic and Non-Chemotherapeutics. The Chemotherapeutic segment held the majority share in 2022 in the Compounding Chemotherapy market data. Chemotherapeutic medicines' greater effectiveness is fostering market expansion. Furthermore, this market's development drivers include the aging population and the rise in cancer incidence.
Based on the delivery method, the Compounding Chemotherapy market segmentation includes Gravimetric Automated Compounding Devices and Volumetric Automated Compounding Devices. The Gravimetric Automated Compounding Device segment dominated the market growth in 2022 and is projected to be the faster-growing segment during the forecast period, 2024-2032. Gravimetric products are simple to use, making them the market leader.
Based on Sterility, the Compounding Chemotherapy market data includes Sterile and Non-Sterile. The Sterile segment dominated the Compounding Chemotherapy market revenue in 2022 and is projected to be the faster-growing segment during the forecast period 2024-2032. High-efficiency injections and infusions must be sterile to meet consumer demand.
Figure 1: Compounding Chemotherapy Market, by Sterility, 2023 & 2032 (USD Billion) 
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Based on Technology, the Compounding Chemotherapy market data includes With Robotic Arms and Without Robotic Arms. The With Robotic Arms segment dominated the Compounding Chemotherapy market revenue in 2022 and is projected to be the faster-growing segment during the forecast period, 2024-2032. Additionally, it is projected to have a high CAGR of 6.4 percent. It is because automated machines are more accurate and predictable.
By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. North America Compounding Chemotherapy market accounted for USD 0.18 billion in 2022 with a share of around 45.80% and is expected to exhibit a significant CAGR growth during the study period. Due to the increasing number of cancer cases, growing healthcare expenses, and the pressing demand for sophisticated Chemotherapy, the American Compounding Chemotherapy market has taken the lead and is expanding at a phenomenal rate. The American industry benefits from the broad emphasis on developing contemporary healthcare practices and enhancing cancer-based treatments. The market value is also driven by the growing older population, which is vulnerable to various cancers. According to the Population Reference Bureau, by 2060, there will be 24% more older adults in the United States than there are today. These figures guarantee that compounded Chemotherapy will continue to be in demand in the upcoming years.
Further, the major countries studied in the market report are The U.S., Canada, Germany, France, the U.K., Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: COMPOUNDING CHEMOTHERAPY MARKET SHARE BY REGION 2022 (%) 
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Because of the spike in government-sponsored research efforts to find a cure for cancer, which are increasing at an alarming rate, the European Compounding Chemotherapy market is anticipated to occupy second place in terms of revenue throughout the analysis period. The high cost of healthcare, the presence of well-known businesses, and the local healthcare infrastructure quality also influence the area's market size. Moreover, the U.K. Compounding Chemotherapy market held the largest market share, and the Germany Compounding Chemotherapy market was the fastest-growing market in the region.
The Asia Pacific Compounding Chemotherapy market is anticipated to grow at a significant rate. Compound chemotherapy sales in Asia pacific are segmented into India, China, South Korea, Japan, and Australia. Since governments in many nations support the healthcare sector with funding for active research and development operations, particularly in China and India, the region offers significant growth potential. Additionally, the region's market size is boosted by the sharp increase in cancer incidence, the huge need for efficient medicines, rapidly aging populations, and rising public awareness of cancer and the most recent treatment choices. Further, the China Compounding Chemotherapy market held the largest market share, and the India Compounding Chemotherapy market was the fastest-growing market in the region.
Compounding Chemotherapy Key Market Players & Competitive Insights
Major industry companies are investing a lot of money in R&D to expand their product offerings, which will spur further market expansion for Compounding Chemotherapy. With significant industry changes, including new product launches, mergers and acquisitions, contractual agreements, higher investments, and collaboration with other organizations, market developments are also undertaking various strategic activities to expand their presence. Compounding Chemotherapy industry competitors must provide affordable products to grow and remain in a market that is becoming increasingly competitive.
Manufacturing locally to cut operational costs is one of the main business methods producers use in the Compounding Chemotherapy industry to benefit customers and increase the market sector. The Compounding Chemotherapy industry has recently given medicine some of the most important advantages. The Compounding Chemotherapy market major player such as Braun Melsungen AG, Pfizer Inc., Baxter, Grifols SA, The Metrix Company, Added Pharma, Equashield, and Millers Pharmacy Company.
Research Triangle Park, North Carolina, serves as the corporate headquarters for the American biopharmaceutical business G1 Therapeutics, Inc. The business focuses on creating and marketing small-molecule therapies for the treatment of cancer patients. In March 2021, Boehringer Ingelheim and G1 Therapeutics Inc. collaborated to release COSELA (dinaciclib) on the American market. The businesses will now market COSELA after the USFDA gave it the go-ahead. It is said to lower the likelihood of chemotherapy-induced myelosuppression in adults when used with an etoposide/platinum-containing regimen for small-cell lung cancer. Combined with Chemotherapy, it is the only cancer treatment that safeguards the bone marrow.
The corporate headquarters of the multinational food and beverage processing conglomerate Nestlé S.A. are in Vevey, Vaud, Switzerland. Since 2014, based on revenue and other indicators, it has been the world's largest publicly traded food company. In 2022, Nestle S.A. stated that the company is investigating cutting-edge Technology to create dairy protein-based products without using animals.
Pfizer Inc. is a worldwide pharmaceutical and biotechnology company with its main office in Manhattan, New York City, on 42nd Street. In March 2021, LORBRENA's indication was expanded to include first-line therapy for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer as a result of the FDA's approval of Pfizer Inc.'s sNDA for LORBRENA. LORBRENA is a third-generation ALK inhibitor created to treat brain metastases and tumor alterations that hasten the development of drug resistance.
Key Companies in the Compounding Chemotherapy market include
• Braun Melsungen AG
• Pfizer Inc.
• Baxter
• Grifols SA
• The Metrix Company
• Added Pharma
• Equashield
• Millers Pharmacy
Compounding Chemotherapy Industry Developments
March 2021:The establishment of Revelation Pharma Corp. has been announced by Osceola Capital and seasoned businessman Jacob Beckel to investigate funding and cooperative arrangements in the pharmaceutical compounding sector.
April 2019:The list of 43 authorized states maintained by Pentec Health, Inc. now includes California. The business provides advanced in-home clinical services, along with patient-specific compounded sterile medications.
May 2019:A contract was reached by Fagron to acquire Central de Drogas, S.A. de C.V., a supplier of raw materials to Mexico's pharmaceutical sector and compounding pharmacies.
Chemotherapeutic
Non-Chemotherapeutics
Gravimetric Automated Compounding Device
Volumetric Automated Compounding Device
Sterile
Non-Sterile
With Robotic Arms
Without Robotic Arms
North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Australia
Rest of Asia-Pacific
Rest of the World
Middle East
Africa
Latin America
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 0.50 billion |
| Market Size 2024 | USD 0.53 billion |
| Market Size 2032 | USD 0.84 billion |
| Compound Annual Growth Rate (CAGR) | 6.01% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2018 - 2021 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Variety, Form, Distribution Channel and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The U.S, Canada, Germany, France, the U.K., Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Braun Melsungen AG, Pfizer Inc., Baxter, Grifols SA, The Metrix Company, Added Pharma, Equashield, Millers Pharmacy. |
| Key Market Opportunities | Opioid scarcity |
| Key Market Dynamics | Technical Advances Cutting-Edge Strategie |
Compounding Chemotherapy Market Highlights:
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
